In the setting of MS relapses, GC could have a dual role, by inhibiting proinflammatory processes [17], but also by increasing the production of anti-inflammatory molecules such as CD39, IL-10 and TGF-β [18–20]. This evidence concerns the gene ENTPD1 and myeloid sarcoma.